+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Obstructive Pulmonary Disease - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

  • ID: 4911391
  • Report
  • October 2019
  • Region: Global
  • 193 pages
  • Transparency Market Research
1 of 3

FEATURED COMPANIES

  • AstraZeneca
  • GlaxoSmithKline plc
  • Mylan N.V.
  • Novartis AG
  • Orion Corporation
  • MORE
Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Scope of the Report

the report on the global chronic obstructive pulmonary disease (COPD) treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period of 2019 to 2027. The report provides the overall market revenue of the global chronic obstructive pulmonary disease treatment market for the period of 2017-2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global chronic obstructive pulmonary disease treatment market during the forecast period.

The report is prepared after extensive research. Primary research involves bulk of the research efforts, wherein, analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global COPD treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of the top-down and bottom-up approaches to study various phenomena in the global chronic obstructive pulmonary disease treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global chronic obstructive pulmonary disease treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global chronic obstructive pulmonary disease treatment market.

The report delves into the competition landscape of the global COPD treatment market. Key players operating in the global chronic obstructive pulmonary disease treatment market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of the players in the global COPD treatment market that have been profiled in this report.

Key Questions Answered in the COPD Treatment Market Report
  • What is the scope of growth for companies in the global chronic obstructive pulmonary disease treatment market?
  • What will be the Y-o-Y growth of the global chronic obstructive pulmonary disease treatment market between 2019 and 2027?
  • Will North America continue to remain the most profitable regional market for COPD treatment providers?
  • Which factors will impede the growth of the global chronic obstructive pulmonary disease treatment market during the forecast period?
  • Which are the leading companies in the global COPD treatment market?
Research Methodology

A unique research methodology has been utilized to conduct a comprehensive research on the growth of the global chronic obstructive pulmonary disease treatment market, and arrive at conclusions on the future growth prospects of the COPD treatment market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary sources referred to by analysts during the production of the global chronic obstructive pulmonary disease treatment market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of The study on the COPD treatment market as primary sources.

These primary and secondary sources have provided exclusive information during interviews, which serves as a validation from chronic obstructive pulmonary disease treatment market leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global chronic obstructive pulmonary disease treatment market with accuracy. The study also uses the top-down approach to assess the numbers for each segment, and the bottom-up approach to counter-validate them. This has helped in reaching estimates on the future prospects of the global chronic obstructive pulmonary disease treatment market more reliably and accurately.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca
  • GlaxoSmithKline plc
  • Mylan N.V.
  • Novartis AG
  • Orion Corporation
  • MORE
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, 2017–2027
4.4.1. Market Revenue (US$ Mn) Projection

5. Market Outlook
5.1. Innovative Solutions for COPD Treatment
5.2. Pipeline Analysis

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
6.3.1. Combination Therapy
6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
6.3.1.3. Triple Therapy
6.3.1.4. Others
6.3.2. Corticosteroids
6.3.3. Bronchodilators
6.3.3.1. Long Acting Beta Agonist (LABA)
6.3.3.2. Short Acting Beta Agonist (SABA)
6.3.3.3. Long Acting Muscarinic Antagonist (LAMA)
6.3.4. Phosphodiesterase Type 4 Inhibitors
6.3.5. Mucokinetics
6.3.6. Others
6.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Drug Class

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Distribution Channel

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by region

9. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
9.2.1. Combination Therapy
9.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
9.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
9.2.1.3. Triple Therapy
9.2.1.4. Others
9.2.2. Corticosteroids
9.2.3. Bronchodilators
9.2.3.1. Long Acting Beta Agonist (LABA)
9.2.3.2. Short Acting Beta Agonist (SABA)
9.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
9.2.4. Phosphodiesterase Type 4 Inhibitors
9.2.5. Mucokinetics
9.2.6. Others
9.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country/Sub-region

10. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
10.2.1. Combination Therapy
10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
10.2.1.3. Triple Therapy
10.2.1.4. Others
10.2.2. Corticosteroids
10.2.3. Bronchodilators
10.2.3.1. Long Acting Beta Agonist (LABA)
10.2.3.2. Short Acting Beta Agonist (SABA)
10.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
10.2.4. Phosphodiesterase Type 4 Inhibitors
10.2.5. Mucokinetics
10.2.6. Others
10.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
11.2.1. Combination Therapy
11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
11.2.1.3. Triple Therapy
11.2.1.4. Others
11.2.2. Corticosteroids
11.2.3. Bronchodilators
11.2.3.1. Long Acting Beta Agonist (LABA)
11.2.3.2. Short Acting Beta Agonist (SABA)
11.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
11.2.4. Phosphodiesterase Type 4 Inhibitors
11.2.5. Mucokinetics
11.2.6. Others
11.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region

12. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
12.2.1. Combination Therapy
12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
12.2.1.3. Triple Therapy
12.2.1.4. Others
12.2.2. Corticosteroids
12.2.3. Bronchodilators
12.2.3.1. Long Acting Beta Agonist (LABA)
12.2.3.2. Short Acting Beta Agonist (SABA)
12.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
12.2.4. Phosphodiesterase Type 4 Inhibitors
12.2.5. Mucokinetics
12.2.6. Others
12.3. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region

13. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
13.2.1. Combination Therapy
13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
13.2.1.3. Triple Therapy
13.2.1.4. Others
13.2.2. Corticosteroids
13.2.3. Bronchodilators
13.2.3.1. Long Acting Beta Agonist (LABA)
13.2.3.2. Short Acting Beta Agonist (SABA)
13.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
13.2.4. Phosphodiesterase Type 4 Inhibitors
13.2.5. Mucokinetics
13.2.6. Others
13.3. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2027
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC
13.4.2. South Africa
13.4.3. Israel
13.4.4. Rest of Middle East & Africa
13.5. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share/ranking Analysis By Company (2018)
14.3. Company Profiles
14.3.1. AstraZeneca
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Boehringer Ingelheim International GmbH
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. GlaxoSmithKline plc
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Novartis AG
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. CHIESI Farmaceutici S.p.A.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Orion Corporation
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Mylan N.V.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
  • CHIESI Farmaceutici S.p.A.
  • Orion Corporation
  • Mylan N.V.
Note: Product cover images may vary from those shown
Adroll
adroll